Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid TumorsSolid TumorsTumorsCancerAdvanced Malignancy
- Interventions
- Drug: Arm 1- Dose EscalationDrug: Arm 1- Dose Expansion
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 95
- Registration Number
- NCT00858377
- Locations
- 🇦🇺
Research Site, Parkville, Victoria, Australia
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Phase 3
Terminated
- Conditions
- CancerNon-Small Cell Lung CancerAnemiaLung Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2549
- Registration Number
- NCT00858364
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 85
- Registration Number
- NCT00853372
"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"
Phase 1
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: MP-376 (Levofloxacin solution for Inhalation)
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 27
- Registration Number
- NCT00840333
European Union Registry in Paediatric Chronic Kidney Disease Patients Looking at Safety and Usage Patterns of Darbepoetin Alfa
Completed
- Conditions
- Chronic Kidney Disease
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 321
- Registration Number
- NCT00838097
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Phase 3
Completed
- Conditions
- Castrate-Resistant Prostate CancerCancerCarcinomaTumorsProstate Cancer
- Interventions
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 384
- Registration Number
- NCT00838201
- Locations
- 🇵🇱
Research Site, Wroclaw, Poland
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Phase 2
Completed
- Conditions
- Colon CancerColorectal CancerRectal CancerMetastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 285
- Registration Number
- NCT00819780
- Locations
- 🇪🇸
Research Site, San Sebastián De Los Reyes, Madrid, Spain
Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 56
- Registration Number
- NCT00818948
- Locations
- 🇲🇽
Research Site, Mexico, Distrito Federal, Mexico
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- OncologyAdvanced MalignancyAdvanced Solid TumorsTumorsCancerOncology Patients
- Interventions
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2014-12-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 54
- Registration Number
- NCT00813384
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Breast NeoplasmsMetastatic CancerTumorsBreast TumorsCancerLocally Recurrent and Metastatic Breast CancerOncologyBreast CancerMetastasesSolid Tumors
- Interventions
- Drug: AMG 386 10 mgkg, Paclitaxel and TrastuzumabDrug: AMG 386 30 mg/kg, Paclitaxel and TrastuzumabDrug: AMG 386 30 mg/kg, Capecitabine and LapatinibDrug: AMG 386 10 mg/kg, Capecitabine and Lapatinib
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 65
- Registration Number
- NCT00807859
- Locations
- 🇫🇷
Research Site, Toulouse, France
© Copyright 2025. All Rights Reserved by MedPath